Question 1

What is the purpose of this trial and how might it help my condition?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT clinical trial (NCT01885897). Contact the study team or your healthcare provider for specific answers.

Question 2

What are the potential side effects of ALT-803?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT clinical trial (NCT01885897). Contact the study team or your healthcare provider for specific answers.

Question 3

How does ALT-803 compare to my current treatment options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT clinical trial (NCT01885897). Contact the study team or your healthcare provider for specific answers.

Question 4

What will my treatment schedule look like if I participate?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT clinical trial (NCT01885897). Contact the study team or your healthcare provider for specific answers.

Question 5

Are there any specific tests or procedures I will need to undergo?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT clinical trial (NCT01885897). Contact the study team or your healthcare provider for specific answers.

Question 6

What support will I have during the trial, especially regarding travel and care?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT clinical trial (NCT01885897). Contact the study team or your healthcare provider for specific answers.

What this study is about